Profile data is unavailable for this security.
About the company
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
- Revenue in USD (TTM)14.02m
- Net income in USD-84.03m
- Incorporated2018
- Employees419.00
- LocationMeiraGTx Holdings PLC450 E 29th St Fl 15NEW YORK 10016-8367United StatesUSA
- Websitehttps://meiragtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | 153.73m | -106.79m | 305.80m | 302.00 | -- | 1.52 | -- | 1.99 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 309.23m | 449.00 | -- | 6.96 | -- | 5.13 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 309.93m | 54.00 | -- | 2.61 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Procaps Group SA | 414.10m | 52.20m | 313.09m | 5.50k | 5.33 | 7.95 | 4.49 | 0.7561 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 316.61m | 7.00 | -- | 1.17 | -- | 273.88 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Cerus Corp | 186.80m | -37.49m | 318.01m | 288.00 | -- | 5.92 | -- | 1.70 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Lyra Therapeutics Inc | 1.56m | -62.68m | 320.07m | 88.00 | -- | 3.36 | -- | 205.43 | -1.32 | -1.32 | 0.0313 | 1.56 | 0.0123 | -- | -- | 17,704.54 | -49.63 | -58.01 | -57.37 | -68.69 | -- | -- | -4,023.11 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Fractyl Health Inc | 120.00k | -94.27m | 320.78m | 102.00 | -- | -- | -- | 2,673.20 | -1.97 | -1.97 | 0.0025 | -0.7881 | -- | -- | -- | 1,176.47 | -- | -- | -- | -- | 35.83 | -- | -64,242.50 | -- | 3.18 | -2.62 | 3.17 | -- | -- | -- | -48.15 | -- | -- | -- |
| MeiraGTx Holdings PLC | 14.02m | -84.03m | 320.89m | 419.00 | -- | 2.30 | -- | 22.89 | -1.58 | -1.58 | 0.2483 | 2.17 | 0.0435 | -- | 0.8908 | 33,453.46 | -26.06 | -26.40 | -33.89 | -32.66 | -- | -- | -599.47 | -420.70 | -- | -91.62 | 0.3429 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.97m | 321.14m | 140.00 | -- | 23.35 | -- | -- | -1.33 | -1.33 | 0.00 | 0.2729 | 0.00 | -- | -- | 0.00 | -81.81 | -- | -131.29 | -- | -- | -- | -- | -- | -- | -37.05 | 0.5359 | -- | -- | -- | -11.06 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 324.03m | 75.00 | -- | 0.5786 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Terns Pharmaceuticals Inc | 0.00 | -90.21m | 328.43m | 66.00 | -- | 1.28 | -- | -- | -1.27 | -1.27 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -32.48 | -41.34 | -33.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.96m | 329.60m | 79.00 | -- | 1.14 | -- | -- | -3.29 | -3.29 | 0.00 | 4.12 | 0.00 | -- | -- | 0.00 | -59.46 | -- | -63.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Organogenesis Holdings Inc | 433.14m | 4.95m | 331.23m | 862.00 | 68.28 | 1.18 | 16.31 | 0.7647 | 0.0368 | 0.0368 | 3.27 | 2.12 | 0.9526 | 4.02 | 5.05 | 502,482.60 | 1.09 | 5.46 | 1.31 | 6.90 | 75.42 | 74.94 | 1.14 | 4.81 | 2.44 | 9.05 | 0.1989 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Caribou Biosciences Inc | 34.48m | -102.07m | 333.27m | 158.00 | -- | 0.8859 | -- | 9.67 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Data as of May 01 2024. Currency figures normalised to MeiraGTx Holdings PLC's reporting currency: US Dollar USD
43.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2023 | 11.33m | 17.82% |
| Adage Capital Management LPas of 31 Dec 2023 | 5.29m | 8.32% |
| Prosight Management LPas of 31 Dec 2023 | 4.05m | 6.37% |
| 683 Capital Management LLCas of 31 Dec 2023 | 2.50m | 3.93% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.98m | 3.11% |
| Royce & Associates LPas of 31 Dec 2023 | 672.12k | 1.06% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 561.62k | 0.88% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 433.25k | 0.68% |
| Geode Capital Management LLCas of 31 Dec 2023 | 387.55k | 0.61% |
| Laurion Capital Management LPas of 31 Dec 2023 | 367.94k | 0.58% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
